Cell And Gene Therapy Contract Development And Manufacturing Organization (CDMO) Market Forecast 2026–2035 Reflecting Expansion Opportunities Across Industries
The Business Research Company’s 2026 market reports include new capabilities such as market attractiveness scoring and analysis, total addressable market analysis, company scoring matrix, interactive excel data dashboard, improved supply chain analysis, upcoming startups in the market, and overview of key products, aimed at improving the depth, usability, and strategic value of the insights delivered.
What Market Size Expansion Is Predicted For The Cell And Gene Therapy Contract Development And Manufacturing Organization (CDMO) Market Between 2026 And 2030?
The cell and gene therapy contract development and manufacturing organization (cdmo) market has seen substantial growth over recent years. It is forecast to increase from $6.92 billion in 2025 to $8.85 billion in 2026, achieving a compound annual growth rate (CAGR) of 27.8%. This past expansion is primarily due to the rising trend of outsourcing advanced therapy manufacturing, insufficient internal development capacities, the emergence of early-stage biotech companies, the broadening scope of orphan drug development, and a growing requirement for specialized expertise.
The cell and gene therapy contract development and manufacturing organization (cdmo) market size is anticipated to undergo significant growth in the upcoming years. It is predicted to expand to $21.35 billion in 2030, achieving a compound annual growth rate (CAGR) of 24.6%. This projected growth can be attributed to the increasing commercialization of gene-modified therapies, a rising demand for flexible manufacturing capacity, the expansion of global cdmo partnerships, growing investment within cell therapy pipelines, and an increase in regulatory approvals for advanced therapies. Notable trends during this forecast period include the broadening of end-to-end cdmo service offerings, an increasing need for commercial-scale manufacturing support, the rising adoption of advanced gene editing platforms, a stronger focus on accelerated development timelines, and enhanced integration of regulatory support services.
Download the Free Sample Report to Explore Key Market Insights:
https://www.thebusinessresearchcompany.com/sample.aspx?id=15753&type=smp
Which Growth Drivers Are Contributing To The Progress Of The Cell And Gene Therapy Contract Development And Manufacturing Organization (CDMO) Market?
An increasing incidence of cancer is anticipated to fuel the expansion of the cell and gene therapy contract development and manufacturing organization (CDMO) market moving ahead. This medical condition is defined by the unrestrained proliferation and dissemination of abnormal cells within the body. The escalating frequency of cancer cases is attributed to factors like an aging populace, evolving lifestyle choices, environmental exposures, and enhanced diagnostic capabilities. The cell and gene therapy contract development and manufacturing organization (CDMO) assists in mitigating cancer prevalence by developing and producing innovative, targeted treatments that boost efficacy and improve patient outcomes. For instance, in July 2024, data from the Australian Institute of Health and Welfare, an Australia-based government agency, indicated that an estimated 165,000 Australians were newly diagnosed with cancer in 2023, which corresponds to over 450 cases each day, with males comprising approximately 55% of these diagnoses. Consequently, the rising occurrence of cancer cases propels the growth of the cell and gene therapy contract development and manufacturing organization (CDMO) market.
Which Market Segments Are Examined In The Cell And Gene Therapy Contract Development And Manufacturing Organization (CDMO) Market Study?
The cell and gene therapy contract development and manufacturing organization (cdmo) market covered in this report is segmented –
1) By Product Type: Gene Therapy, Gene-Modified Cell Therapy, Cell Therapy
2) By Phase: Phase 1, Phase 2, Phase 3
3) By Indication: Oncology, Infectious Diseases, Neurological Disorders, Rare Diseases, Other Indications
Subsegments:
1) By Gene Therapy: Viral Vector-Based Gene Therapy, Non-Viral Gene Therapy, Plasmid DNA-Based Gene Therapy
2) By Gene-Modified Cell Therapy: CAR-T Cell Therapy, TCR-T Cell Therapy, NK Cell Therapy
3) By Cell Therapy: Stem Cell Therapy, Progenitor Cell Therapy, Immune Cell Therapy
Which Trends Are Impacting The Growth Of The Cell And Gene Therapy Contract Development And Manufacturing Organization (CDMO) Market?
Major companies operating within the cell and gene therapy contract development and manufacturing organization (CDMO) market are dedicated to enhancing their service portfolios with sophisticated solutions, such as PluriMatrix technology, to boost the scalability, efficiency, and quality of cell-based product manufacturing. PluriMatrix technology is a proprietary system specifically designed for the large-scale production of cell-based products. This advanced technology enables the 3D expansion of cells at an industrial scale, ensuring high yield and consistent quality through an automated, fully controlled, and validated process. For instance, in January 2024, Pluri, an Israel-based biotech company, launched PluriCDMO, a new business division offering cell therapy manufacturing services as a contract development and manufacturing organization (CDMO). This new division includes a 47,000-square-foot good manufacturing practice (GMP) cell therapy production facility. Pluri’s newly established division provides comprehensive services from early preclinical stages to late-stage clinical trials and commercialization, encompassing process and analytical development, scale-up, validation, logistics, automation, and regulatory-approved comparability studies, as detailed in a company announcement. It leverages the company’s cutting-edge PluriMatrix technology to deliver advanced cell therapy manufacturing services.
Who Are The Primary Competitors In The Cell And Gene Therapy Contract Development And Manufacturing Organization (CDMO) Market?
Major companies operating in the cell and gene therapy contract development and manufacturing organization (cdmo) market are Lonza Group, Catalent Inc, Thermo Fisher Scientific Inc, Samsung Biologics Co Ltd, WuXi Biologics, AGC Biologics, FUJIFILM Diosynth Biotechnologies, Oxford BioMedica Plc, Recipharm AB, Almac Group Ltd, KBI Biopharma, Rentschler Biopharma, Avid Bioservices Inc, Charles River Laboratories International Inc, VGXI Inc, Genezen Laboratories Inc, OmniaBio Inc, Pluri Inc, Cell and Gene Therapy Catapult, BioVectra Inc, Porton Advanced Solutions Ltd
Read the full cell and gene therapy contract development and manufacturing organization (cdmo) market report here:
What Are The Leading Geographic Regions In The Cell And Gene Therapy Contract Development And Manufacturing Organization (CDMO) Market?
North America was the largest region in the cell and gene therapy contract development and manufacturing organization (CDMO) market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the cell and gene therapy contract development and manufacturing organization (cdmo) market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Request A Tailored Cell And Gene Therapy Contract Development And Manufacturing Organization (CDMO) Market Research Report For Competitive Advantage:
https://www.thebusinessresearchcompany.com/customise?id=15753&type=smp
Browse Through More Reports Similar to the Global Cell And Gene Therapy Contract Development And Manufacturing Organization (CDMO) Market 2026, By The Business Research Company
Cell And Gene Therapy Manufacturing Services Market
Genes Therapy Global Market Report
https://www.thebusinessresearchcompany.com/report/genes-therapy-global-market-report
Cell And Gene Therapy Supply Chain Or Logistics Global Market Report
Get in touch with us:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas +1 310-496-7795
Asia +44 7882 955267 & +91 8897263534
Europe +44 7882 955267
Email us at info@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model
